MADISON, N.J., May 17, 2011 /PRNewswire/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the world's leading provider of
diagnostic testing, information and services, announced today the
successful completion of its acquisition of Celera Corporation
(NASDAQ: CRA). The acquisition was completed by means of a
short-form merger under Delaware
law, under which a wholly owned subsidiary of Quest Diagnostics was
merged with and into Celera, with Celera surviving the merger as a
wholly owned subsidiary of Quest Diagnostics. As a result of
the merger, each share of Celera common stock (other than shares
held by Celera, Quest Diagnostics or any of their respective
affiliates, or shares held by stockholders that properly exercise
appraisal rights under Delaware
law) was converted into the right to receive the same $8 in cash, without interest and less any
withholding of taxes, that was paid in the tender offer for all
outstanding shares of Celera common stock, which expired on
May 10.
Also, as a result of the merger, Celera shares ceased to be
traded on the NASDAQ Global Select Market and Celera will no longer
have reporting obligations under the Securities Exchange Act of
1934, as amended.
Holders of Celera shares of common stock that did not tender
their shares into the tender offer will receive by mail written
instructions for surrendering their share certificates or
transferring their book-entry shares, including a letter of
transmittal, and information regarding the exercise of appraisal
rights under Delaware law.
About Quest Diagnostics
Quest Diagnostics is the world's leading provider of diagnostic
testing, information and services that patients and doctors need to
make better healthcare decisions. The company offers the
broadest access to diagnostic testing services through its network
of laboratories and patient service centers, and provides
interpretive consultation through its extensive medical and
scientific staff. Quest Diagnostics is a pioneer in
developing innovative new diagnostic tests and advanced healthcare
information technology solutions that help improve patient care.
Additional company information is available at:
www.questdiagnostics.com.
Contacts:
Kathleen Valentine (Investors):
973-520-2900
Gary Samuels (Media):
973-520-2800
SOURCE Quest Diagnostics Incorporated